Voyager Therapeutics (VYGR) Stock: Buy, Sell, or Hold?
VYGR - Voyager Therapeutics, Inc. Common Stock
$1.74
-0.12 (-6.45%)
▼
5d:
-8.42%
30d:
-37.86%
90d:
-43.69%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 09, 2026
16d
Get Alerted When VYGR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: VYGR shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: VYGR shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: VYGR is currently trading at $1.74, which is considered oversold relative to its 30-day fair value range of $2.14 to $2.95.
Technical Outlook: Technically, VYGR is in a strong downtrend. The price is currently testing key support at $1.74. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: VYGR scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.89 (+700.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VYGR is in a strong downtrend. The price is currently testing key support at $1.74. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: VYGR scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.89 (+700.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.14 -
$2.95
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.5%)
- BULLISH: Trading 700.5% below Wall St target ($14.89)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.14 -
$2.95
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.74
Resistance Level
$2.47
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.45
Wall Street Target
$14.89
(+700.5%)
Revenue Growth (YoY)
-39.1%
Share & Embed Analysis
Last updated: October 23, 2026 4:00 PM ET
Data refreshes hourly during market hours. Next update: 5:00 PM
Data refreshes hourly during market hours. Next update: 5:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VYGR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 61 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 61 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 50 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 48 HOLD |
